Business
Immatics Announces Full Year 2024 Financial Results and Business Update
Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment continues as plannedACTengine® IMA203 TCR-T (PRAME): Phase 1b IMA203 data published in October 2024 demonstrated a confirmed ORR of 54%, 12.1 months mDOR, 6 months mPFS and OS not reached at a mFU time of 8.6 months in advanced melanoma patients; next data update on Phase 1b trial with extended follow-up planned in 2025 Second-generation
About this update from Immatics N.v.
[{"type":"image","alt":"https://immatics.com/","displaySize":"","headline":null,"caption":"https://immatics.com/","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":111,"url":"https://media.zenfs.com/en/globenewswire.com/1304d6da4a2e1904f1143022249119ce"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GNZ6JLUt9xQWI9XKWr6tFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1304d6da4a2e1904f1143022249119ce","width":300,"height":111}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment continues as planned","length":181,"tagName":"p"}]},{"val":[{"type":"text","content":"ACTengine® IMA203 TCR-T (PRAME): Phase 1b IMA203 data published in October 2024 demonstrated a confirmed ORR of 54%, 12.1 months mDOR, 6 months mPFS and OS not reached at a mFU time of 8.6 months in advanced melanoma patients; next data update on Phase 1b trial with extended follow-up planned in 2025 ","length":301,"tagName":"p"}]},{"val":[{"type":"text","content":"Second-generation ACTengine® IMA203CD8 TCR-T (PRAME): Phase 1a data published in November 2024 showed enhanced pharmacology and potency, demonstrating potential to address solid tumor indications with both high- and medium-level PRAME copy numbers; dose escalation advancing as planned; next data update including ovarian cancer data planned in 2025","length":349,"tagName":"p"}]},{"val":[{"type":"text","content":"TCER® IMA402 (PRAME): Phase 1a data published in November 2024 demonstrated a favorable tolerability profile and initial clinical anti-tumor activity associated with dose and PRAME expression; dose escalation advancing as planned; next data update planned in 2025","length":263,"tagName":"p"}]},{"val":[{"type":"text","content":"TCER® IMA401 (MAGEA4/8): Phase 1a data published in September 2024 demonstrated clinical anti-tumor activity in multiple tumor types and manageable tolerability profile; monotherapy and checkpoint inhibitor combination dose refinement ongoing; next data update with a focus on head and neck cancer planned in 2025","length":313,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash and cash equivalents as well as other financial assets amount...